NetworkNewsBreaks – Aethlon Medical, Inc. (NASDAQ: AEMD) Receives National Cancer Institute Contract Award toward Aethlon Hemopurifier® Investigation
Aethlon Medical (NASDAQ: AEMD) this morning said that it has been awarded a government contract by the National Cancer Institute (NCI). The phase I contract is entitled "Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes." The full amount of the firm fixed price contract is $299,250, which the company will use toward its ongoing examination of the potential use of the Aethlon Hemopurifier® to reduce the presence of circulating tumor-derived exosomes (oncosomes), which contribute to cancer progression. The contract period begins September 15 and will end on June 14, 2018. To view the full press release, visit: http://nnw.fm/R9wBU…







